OncoMatch/Clinical Trials/NCT07813637
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
Official title: A Phase 1 Open-Label, Multicenter Study of JANX013 Combined With JANX007 in Participants With Metastatic Castration Resistant Prostate Cancer
Is NCT07813637 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies multiple treatments including JANX013 and JANX007 for prostate cancer.
Treatment: JANX013 · JANX007 — This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX013 in combination with JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Demographics
Prior therapy
Must have received: androgen receptor pathway inhibitor (abiraterone acetate, enzalutamide, apalutamide, darolutamide)
Have received at least 1 novel ARPI (e.g., abiraterone acetate, enzalutamide, apalutamide, or darolutamide) in any setting
Cannot have received: CAR-T cell therapy
Prior treatment with any chimeric antigen receptor (CAR) T-cell therapy
Cannot have received: T-cell engager
Prior treatment with any approved or investigational TCE
Cannot have received: T-cell costimulatory agent
Prior treatment with any T-cell costimulatory agent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarah Cannon Research Institute · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07813637 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, T-cell engager, T-cell costimulatory agent disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages